Royal Fund Management LLC Lowers Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Royal Fund Management LLC lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 39.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 9,045 shares of the company’s stock after selling 5,900 shares during the period. Royal Fund Management LLC’s holdings in Moderna were worth $900,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRNA. Arlington Trust Co LLC raised its position in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the last quarter. GPS Wealth Strategies Group LLC increased its holdings in Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after buying an additional 180 shares in the last quarter. Archer Investment Corp increased its holdings in Moderna by 71.2% in the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after buying an additional 222 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Moderna by 44.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after buying an additional 175 shares in the last quarter. Finally, Hexagon Capital Partners LLC increased its holdings in Moderna by 182.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 610 shares of the company’s stock worth $61,000 after buying an additional 394 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Royal Bank of Canada lifted their price objective on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday. Canaccord Genuity Group lifted their price objective on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday. Oppenheimer boosted their price target on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $129.55.

Moderna Price Performance

NASDAQ MRNA traded down $0.59 during trading hours on Friday, reaching $125.00. The company’s stock had a trading volume of 4,513,133 shares, compared to its average volume of 3,445,723. The firm’s 50-day moving average price is $105.05 and its 200-day moving average price is $94.37. The company has a quick ratio of 3.36, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $142.79. The company has a market capitalization of $47.86 billion, a price-to-earnings ratio of -7.98 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same period in the previous year, the firm earned $0.19 EPS. The firm’s revenue was down 91.0% compared to the same quarter last year. On average, equities research analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO James M. Mock sold 705 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 139,954 shares of company stock valued at $14,822,576. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.